US Edition
Cyclerion Provides Public Listing Vehicle for Korsana in $380M Deal
The combined company will trade as Korsana Biosciences and use the financing to fund operations into 2029, with Alzheimer’s data expected in 2027.
- On Wednesday, April 1, 2026, Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. announced a definitive all-stock merger agreement, with the combined company operating as Korsana Biosciences, Inc. and trading on Nasdaq under ticker symbol KRSA.
- Korsana secured commitments for an oversubscribed private investment of approximately $380 million to fund operations through 2029 and advance its lead program, KRSA-028, a next-generation monoclonal antibody targeting amyloid beta for Alzheimer's disease treatment.
- Pre-Merger Cyclerion shareholders are expected to own approximately 1.5% of the combined company, while Korsana stockholders will own approximately 98.5% under Dr. Jonathan Violin, Korsana's President and Chief Executive Officer.
- The combined company's cash runway is anticipated to fund operations into 2029, supporting multiple clinical milestones including Phase 1 healthy volunteer data in mid-2027 and amyloid plaque clearance results by end-2027.
- Expected to close in the third quarter of 2026, the transaction remains subject to stockholder approval and regulatory clearances, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
12 Articles
12 Articles
Hastings Tribune
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
WALTHAM, Mass.--(BUSINESS WIRE)--Apr 1, 2026-
Korsana Biosciences Emerges from Cyclerion Merger with $380 Million and a Next-Generation Shot at Alzheimer's - Channelchek
A small-cap reverse merger is giving birth to one of the better-funded Alzheimer’s plays to hit the public markets in recent memory. Cyclerion Therapeutics (Nasdaq: CYCN) and privately-held Korsana Biosciences announced a definitive all-stock merger agreement that will effectively hand the Nasdaq listing to Korsana, with the combined company rebranding as Korsana Biosciences and trading under the new ticker “KRSA.” The deal comes packaged with s…
CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline
Shares of Cyclerion Therapeutics Inc. skyrocketed more than 313% Wednesday, surging from around $1.55 at Tuesday's close to trade near $6.47 midday as the micro-cap biotech announced a transformative all-stock merger with privately held Korsana Biosciences Inc.
Paragon offshoot Korsana to go public in reverse merger for Alzheimer's work
Jonathan Violin loves a reverse merger, and so does Paragon Therapeutics. Violin is taking Korsana Biosciences' fight against Alzheimer's public. Korsana will gain access to more capital as it rides the tailwinds of Roche's similar ...
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
